Abstract:Background: One of the crucial challenges for the future of therapeutic approaches to Alzheimer's disease (AD) is to target the main pathological processes responsible for disability and dependency. However, a progressive cognitive impairment occurring after the age of 70, the main population affected by dementia, is often related to mixed lesions of neurodegenerative and vascular origins. Whereas young patients are mostly affected by pure lesions, ageing favours the occurrence of co-lesions of AD, cerebrovascular disease (CVD) and Lewy body dementia (LBD). Most of clinical studies report on functional and clinical disabilities in patients with presumed pure pathologies. But, the weight of co-morbid processes involved in the transition from an independent functional status to disability in the elderly with co-lesions still remains to be elucidated. Neuropathological examination often performed at late stages cannot answer this question at mild or moderate stages of cognitive disorders. Brain MRI, Single Photon Emission Computed Tomography (SPECT) with DaTscan®, amyloid Positron Emission Tomography (PET) and CerebroSpinal Fluid (CSF) AD biomarkers routinely help in performing the diagnosis of underlying lesions. The combination of these measures seems to be of incremental value for the diagnosis of mixed profiles of AD, CVD and LBD. The aim is to determine the clinical, neuropsychological, neuroradiological and biological features the most predictive of cognitive, behavioral and functional impairment at 2 years in patients with co-existing lesions. Methods: A multicentre and prospective cohort study with clinical, neuro-imaging and biological markers assessment will recruit 214 patients over 70 years old with a cognitive disorder of AD, cerebrovascular and Lewy body type or with coexisting lesions of two or three of these pathologies and fulfilling the diagnostic criteria for dementia at a mild to moderate stage. Patients will be followed every 6 months (clinical, neuropsychological and imaging examination and collection of cognitive, behavioural and functional impairment) for 24 months. Discussion: This study aims at identifying the best combination of markers (clinical, neuropsychological, MRI, SPECT-DaTscan®, PET and CSF) to predict disability progression in elderly patients presenting coexisting patterns. Trial registration: NCT02052947 .

Intérêt des biomarqueurs

Identification de biomarqueurs longitudinaux dans les ataxies spinocérébelleuses

Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults

Étude prospective des biomarqueurs de marche et d’IRM multimodale chez les patients de la cohorte GAIT’N’PARK présentant une atrophie multisystématisée

Analyse intrathécale comparative des chimiokines liées aux lymphocytes B au cours des maladies inflammatoires du système nerveux central

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

BD-tau plasmatique : un biomarqueur spécifique de la gravité de la maladie et de sa dynamique à travers le spectre de la maladie d’Alzheimer

Irm À 7 Tesla Et Sclérose En Plaques: Innovations Et Nouvelles Perspectives

Augmentation Du Taux De Détection Des Patients Présentant Des Nouvelles Lésions De Sep Grâce À L'Utilisation D'Un Outil D'Ia D'Aide À La Décision Clinique

Évaluation longitudinale de patients CMT1A sur 1 an : apport de l’IRM neuromusculaire quantifiée

Facteurs de risque environnementaux de la sclérose en plaques

Corrélation entre le score d’inflammation de bas grade lors de la phase aiguë de l’AVC, sa gravité et son impact sur le pronostic fonctionnel

Study protocol on Alzheimer's disease and related disorders: focus on clinical and imaging predictive markers in co-existing lesions

Cohortes digitales, mythe ou réalité ? Analyse descriptive des utilisateurs français de MSCopilot®

Detecting Alzheimer's disease biomarkers: From antibodies to new bio-mimetic receptors and their application to established and emerging bioanalytical platforms - A critical review

La Volumétrie Cérébrale Pour L'Aide Au Diagnostic Différentiel Des Troubles Neurodégénératifs

Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention

Kallikrein-related peptidase's significance in Alzheimer's disease pathogenesis: A comprehensive survey

Acute ischemic stroke biomarkers: a new era with diagnostic promise?

Biomarkers of Motor Outcomes After Stroke

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers